Oncorena aims to save human lives by transforming a natural substance into a breakthrough treatment for METASTATIC RENAL CANCER.

Read more

Are you or do you have possible candidates for our clinical trials?

We are looking for patients who suffer from metastatic renal cancer and would like to participate in a clinical trial to test a new potential treatment. The objective of the study is to evaluate the safety, tolerability, and anti-tumor efficacy of orellanine treatment in patients with Metastatic Clear-Cell or Papillary Renal Cell Carcinoma. Find out more about the trial and check your or your candidate’s eligibility here: 

Read more
Alternate Text

Urgent and major unmet medical need


Oncorena breaks new ground in developing an innovative treatment for patients with metastatic renal cancer. About one-third of kidney cancer patients are diagnosed with this fatal disease and...

Building value based on clinical validation


Responding to this challenge, Oncorena is developing a potentially curative treatment based on orellanine, a naturally occurring substance from the Cortinarius family of mushrooms...

Our research makes a difference


Oncorena has completed all preclinical studies and has initiated early-stage clinical development...

Latest News

Jack Photo Interview

Get to know our Chief Medical Officer – Jack Welch

Oncorena is undergoing a first-in-human phase 1/2 clinical trial for ONC-175, and at the bow is Jack Welch, Chief Medical Officer (CMO), overseeing operations. With a longstanding career…

Read more
Borje Harldsson 4 Stor 920X400 (1)

Börje Haraldsson – CEO at Oncorena

In 2011, the pharmaceutical company Oncorena was founded with the mission to develop a breakthrough treatment for me…

Read more
Åsaholmgren 23

Oncorena appoints Åsa Holmgren as Head of Regulatory Affairs

Oncorena is adding a new member to the team - Åsa Holmgren is appointed Head of Regulatory Affairs. With a MSc Pharm…

Read more
Oncorena 2023 Team3

Oncorena appoints Susanna Dahlgren as Chief Operating Officer

Susanna Dahlgren now joins Oncorena as Chief Operating Officer, having supported the company for approximately one y…

Read more

Quick Facts